Advertisement
Screener

MARKER THERAPEUTICS, INC. (MRKR) Research and Development in Process

2.8 / 5 stars · 68/120 Roast Me

MARKER THERAPEUTICS, INC. Research and Development in Process

MARKER THERAPEUTICS, INC. (MRKR) reported Research and Development in Process of $116.04 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentInProcess · last filed 2020-03-12

  • MARKER THERAPEUTICS, INC. research and development in process for fiscal 2018 was $116.04M.
  • MARKER THERAPEUTICS, INC. research and development in process for fiscal 2017 was $0.00.
Period endResearch and Development in Process 12 monthResearch and Development in Process 179 month
2018-12-31$116.04M
10-K · filed 2020-03-12
2017-12-31$0.00
10-K · filed 2019-03-15
2014-06-30$612.00K
10-Q · filed 2014-08-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66